2018/02/20 by Reetobrata Basu, Yanrong Qian, John J. Kopchick · 1 citation
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer, Hypoxia, and Metabolism #Growth Hormone and Insulin-like Growth Factors #Pituitary Gland Disorders and Treatments
paper · pdf · doi:10.1530/eje-18-0018
openalex publication_date 2018/02/20 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/15
Growth hormone (GH) is produced primarily by anterior pituitary somatotroph cells. Numerous acute human (h) GH treatment and long-term follow-up studies and extensive use of animal models of GH action have shaped the body of GH research over the past 70 years. Work on the GH receptor (R)-knockout (GHRKO) mice and results of studies on GH-resistant Laron Syndrome (LS) patients have helped define many physiological actions of GH including those dealing with metabolism, obesity, cancer, diabetes, cognition and aging/longevity. In this review, we have discussed several issues dealing with these biological effects of GH and attempt to answer the question of whether decreased GH action may be beneficial.